Kyoung Soo Ha

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 11

Top Topics

African American

Circulating Tumor

Top Venues

Investigational new drugs

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Hyun Chul Kim, Eunsol Yang, Soyoung Lee, Jaeseong Oh, Myongjae Lee, ChaeEun Lee, Kyoung Soo Ha, Won Sik Choy, In-Jin Jang, Kyung-Sang Yu
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects. Investigational new drugs 42 (1) (2023)
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Choy
Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular cancer therapeutics (2023)
Hyun Chul Kim, Eunsol Yang, Soyoung Lee, Jaeseong Oh, Myongjae Lee, ChaeEun Lee, Kyoung Soo Ha, Won Sik Choy, In-Jin Jang, Kyung-Sang Yu
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects. Investigational new drugs 42 (1) (2023)
Hyun Chul Kim, Eunsol Yang, Soyoung Lee, Jaeseong Oh, Myongjae Lee, ChaeEun Lee, Kyoung Soo Ha, Won Sik Choy, In-Jin Jang, Kyung-Sang Yu
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects. Investigational new drugs (2023)
Hyun Chul Kim, Eunsol Yang, Soyoung Lee, Jaeseong Oh, Myongjae Lee, ChaeEun Lee, Kyoung Soo Ha, Won Sik Choy, In-Jin Jang, Kyung-Sang Yu
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects. Investigational new drugs 42 (1) (2023)
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Choy
Venadaparib is a novel and selective PARP inhibitor with improved physicochemical properties, efficacy, and safety. Molecular cancer therapeutics (2023)
Hyun Chul Kim, Eunsol Yang, Soyoung Lee, Jaeseong Oh, Myongjae Lee, ChaeEun Lee, Kyoung Soo Ha, Won Sik Choy, In-Jin Jang, Kyung-Sang Yu
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects. Investigational new drugs 42 (1) (2023)
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Choy
Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular cancer therapeutics 22 (3) (2023)
Hyun Chul Kim, Eunsol Yang, Soyoung Lee, Jaeseong Oh, Myongjae Lee, ChaeEun Lee, Kyoung Soo Ha, Won Sik Choy, In-Jin Jang, Kyung-Sang Yu
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects. Investigational new drugs 42 (1) (2023)
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Choy
Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular cancer therapeutics 22 (3) (2023)
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Choy
Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular cancer therapeutics 22 (3) (2023)